Dyslexia Treatment Market to Reap Excessive Revenues by 2025

Posted by vinit sawant on April 30th, 2021

Market Highlights

The growth of the global dyslexia treatment market is driven by various factors such as increased spending in public health care on mental health drives the market growth. However, the low awareness about diagnosis and treatment of dyslexia, and the inefficient mental health infrastructure is projected to hamper the growth of the global dyslexia treatment market.

According to MRFR analysis, the global dyslexia treatment market growth is expected to register a CAGR of 6.5% during the forecast period of 2019 to 2025 and is expected to reach USD 26,884.5 Million by 2025.

Segmentation 

The global dyslexia treatment market has been segmented based on type of dyslexia, treatment, route of administration, and end user.

The market, based on type of dyslexia, has been divided into phonological dyslexia and surface dyslexia. The phonological dyslexia segment is likely to be the largest and fastest-growing segment.

The global dyslexia treatment market has been segmented, on the basis of treatment, into drug class, tools, and educational techniques. The drug class segment is expected to be the largest segment owing to the increased funding to develop drugs to treat neurological disorders.

On the basis of end users of the market have been segmented into psychiatric institutions, rehabilitation centers, home care, and others. The mental institutions segment is expected to hold the largest share of the market due to the increasing number of treatment centers for dyslexia.

Key Players

Some of the key players in the global dyslexia treatment market are Jubilant Cadista (US), Pfizer Inc (US), Micro Labs (India), Gangwal Chemicals Pvt. Ltd (India), Srikem Labs (India), Novartis AG (UK), Purdue Pharma (US), RPG Life Sciences Ltd. Cian Healthcare Pvt. Ltd (India), GlaxoSmithKline (UK), Teva Pharmaceutical Industries Ltd (Israel), Eli Lilly & Company (US), and Wallace Pharmaceuticals Ltd (US).